On this basis, we hypothesized that a treatment with agonistic anti-OX40 antibody alongside the TLR9 ligand, unmethylated CpG oligodeoxynucleotide will help to induce antitumor immune responses and eliminate established bladder tumor (MB49) and metastases as well. This evidence concerns the gene TLR9 and urinary bladder neoplasm.